drugset / Trial / NCT05543681
Clinical Trial on Agitation in Alzheimer's Dementia
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Timeline
- Start
- 2022-10-11
- Primary completion
- 2026-08
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Melatonin | Small molecule | — | Oral |
| Comparator | delta-9-tetrahydrocannabinol | Other / unclassified | — | Oral |